Language / Ngôn ngữ:
McKaizer Institute — Longevity & Wellness Science
The definitive science-backed guide to reversing cellular aging through senolytics, NAD+ restoration, and sirtuin activation. Protocols from Harvard, Mayo Clinic, and Stanford — made actionable.
50%
decline in cellular NAD+ levels between age 20 and 50 — the central energy crisis of biological aging
Table of Contents
- The Day Aging Became a Treatable Condition
- Senescent Cells — The Zombie Crisis Spreading Through Your Body
- Senolytics — Clearing the Cellular Debris
- NAD+ — The Master Energy Molecule Collapsing With Age
- Sirtuins — Your Longevity Genes Waiting to Be Activated
- The Complete Cellular Rejuvenation Protocol
- Measuring Your Biological Age
- The 250-Year Horizon
- Frequently Asked Questions (20)
The Day Aging Became a Treatable Condition
The Day Aging Became a Treatable Condition
For most of human history, aging was destiny. It arrived like weather — inevitable, unquestioning, beyond intervention. We treated its symptoms — the arthritis, the heart disease, the cognitive decline — but never the underlying process itself.
That paradigm has now shattered.
In January 2023, the World Health Organization quietly made one of the most consequential decisions in medical history. They added a new extension code to the International Classification of Diseases: XT9T, “Ageing-related.” For the first time, the global health authority acknowledged that aging itself — not just its downstream diseases — could be a legitimate target for medical intervention.
From Inevitable to Treatable: A Scientific Revolution
The shift didn’t happen overnight. It was the culmination of three decades of painstaking research that fundamentally rewired our understanding of why we age.
Dr. Cynthia Kenyon at the University of California, San Francisco, struck the first blow in 1993. Her team discovered that a single gene mutation in the roundworm C. elegans could double the organism’s lifespan. The gene — daf-2 — controlled insulin signaling. Suddenly, longevity wasn’t mystical. It was mechanistic.
Then came the landmark 2013 paper that changed everything.
Published in Cell and authored by Dr. Carlos López-Otín of the University of Oviedo alongside collaborators including Maria Blasco and Manuel Serrano, “The Hallmarks of Aging” identified nine distinct biological processes that drive human aging:
- Genomic instability — accumulated DNA damage over time
- Telomere attrition — the shortening of chromosome-protective caps
- Epigenetic alterations — disrupted gene expression patterns
- Loss of proteostasis — protein quality control failures
- Deregulated nutrient sensing — metabolic pathway dysfunction
- Mitochondrial dysfunction — energy production decline
- Cellular senescence — accumulation of “zombie” cells
- Stem cell exhaustion — reduced regenerative capacity
- Altered intercellular communication — chronic inflammation signals
💡 Quick Fact: The original 2013 “Hallmarks of Aging” paper has been cited over 25,000 times — making it one of the most influential biology papers of the 21st century. In 2023, the authors published an update adding three new hallmarks, including disabled macroautophagy and chronic inflammation.
What This Means For You
This framework matters because it transforms aging from an abstract inevitability into a collection of addressable biological problems. Each hallmark is a target. Each target can, in principle, be modified.
You’re no longer fighting “getting old.” You’re addressing specific cellular processes — many of which respond to interventions available today.
The Drug That Proved It Possible
If the Hallmarks paper was the map, rapamycin was the proof of concept.
Originally isolated from soil bacteria on Easter Island (Rapa Nui), this compound was first used as an immunosuppressant in organ transplants. Then researchers noticed something remarkable: transplant patients on rapamycin experienced lower rates of age-related cancer.
In 2009, Dr. David Harrison and colleagues at the Jackson Laboratory published a landmark study in Nature. Their finding stunned the field: rapamycin extended median lifespan in mice by 9–14%, even when administered late in life. It was the first time a drug had extended lifespan in mammals.
The mechanism? Rapamycin inhibits mTOR (mechanistic target of rapamycin), a nutrient-sensing pathway that, when overactive, accelerates aging processes.
- Caloric restriction works partly by dampening mTOR
- Intermittent fasting influences the same pathway
- Exercise creates beneficial mTOR oscillation patterns
Suddenly, researchers had chemical confirmation that aging’s biological clockwork could be slowed — with a single molecule.
The Regulatory Breakthrough
Science moved. But institutions moved slower.
For years, the FDA refused to approve clinical trials targeting “aging” as a condition. There was no diagnostic code. No recognized disease state. Companies couldn’t run trials, couldn’t secure funding, couldn’t bring interventions to market.
Dr. Nir Barzilai at Albert Einstein College of Medicine spent over a decade navigating this bureaucratic maze. His proposed TAME (Targeting Aging with Metformin) trial became a test case for whether regulators would accept aging as a legitimate therapeutic target.
In 2015, the FDA finally agreed. The TAME trial — now underway — is testing whether metformin, a $4-per-month diabetes drug, can delay the onset of age-related diseases in healthy older adults.
The trial’s design was revolutionary:
- 3,000 participants aged 65–79
- Primary endpoint: time to any major age-related disease
- Not treating one disease — treating the underlying aging process
This represented a philosophical shift. Aging wasn’t a background condition anymore. It was a treatable state.
What This Means For You
You are living through the first generation where aging is officially recognized as modifiable biology. The frameworks exist. The targets are identified. The regulatory pathways — imperfect but functional — are opening.
The question is no longer if aging can be slowed. It’s how aggressively you engage with the interventions already available — and which emerging therapies you position yourself to access.
The Longevity Medicine Ecosystem Today
The infrastructure is building rapidly.
Dr. Peter Attia — trained at Johns Hopkins and Stanford — now operates one of the most sought-after longevity medicine practices in the United States. His framework focuses on what he calls “Medicine 3.0”: proactive intervention decades before disease manifests.
Academic centers are following. Stanford’s Center on Longevity, the Buck Institute for Research on Aging, and Harvard’s Sinclair Lab now attract billions in combined research funding.
Private capital has flooded the space:
- Altos Labs launched in 2022 with $3 billion in funding
- Calico (backed by Google) has spent over $2.5 billion since 2013
- Unity Biotechnology, Life Biosciences, and Loyal target specific aging pathways
💡 Quick Fact: In 2023 alone, longevity-focused biotechnology startups raised over $5.2 billion in venture funding — more than triple the amount from five years prior.
Key Points
- Aging now has an official medical classification — the WHO’s XT9T code legitimizes it as a treatable condition, not just an inevitable decline
- The Hallmarks of Aging framework identifies nine (now twelve) specific biological processes that drive aging — each representing a therapeutic target
- Rapamycin, metformin, and emerging interventions demonstrate that aging’s core mechanisms respond to pharmacological modification — moving longevity medicine from theory to clinical reality
Senescent Cells — The Zombie Crisis Spreading Through Your Body
Senescent Cells — The Zombie Crisis Spreading Through Your Body
They refuse to die. They refuse to work. And they’re slowly poisoning everything around them.
Senescent cells — sometimes called “zombie cells” — represent one of the most insidious drivers of aging. These are cells that have stopped dividing but won’t undergo the programmed death (apoptosis) that normally clears damaged cells from your tissues.
Instead, they linger. They accumulate. And they secrete a toxic cocktail of inflammatory signals that accelerates aging in every organ they touch.
How Normal Cells Become Zombies
Every cell in your body faces a choice when it encounters damage — repair, replicate, die, or enter senescence.
Cellular senescence evolved as a tumor-suppression mechanism. When a cell’s DNA becomes too damaged to safely replicate, senescence acts as an emergency brake. The cell permanently exits the division cycle, preventing potential cancer.
In youth, this system works beautifully. Your immune system efficiently identifies and clears senescent cells. The brake gets applied, the damaged cell gets removed, tissue integrity remains intact.
But as we age, two things go wrong:
- Senescent cell production accelerates — more cellular damage, more oxidative stress, more replication errors
- Immune clearance declines — an aging immune system becomes less efficient at identifying and eliminating zombie cells
The result is accumulation. By age 60, senescent cell burden can be 10 to 15 times higher than at age 25. By 80, certain tissues become overwhelmed.
💡 Quick Fact: Research from the Mayo Clinic found that senescent cells make up only 1-2% of total cells in aged tissues — yet this tiny fraction drives a disproportionate amount of age-related dysfunction.
What This Means For You
Your body’s tumor-prevention system becomes its own liability over time. The mechanism that protected you from cancer in your twenties becomes a source of chronic inflammation in your sixties.
Understanding this shift reframes aging itself — not as general decay, but as the failure of specific maintenance systems.
The SASP Problem — When Zombie Cells Attack Their Neighbors
Senescent cells don’t just occupy space. They actively damage surrounding tissue through something called the Senescence-Associated Secretory Phenotype — or SASP.
Dr. Judith Campisi at the Buck Institute for Research on Aging pioneered SASP research over two decades. Her work revealed that senescent cells continuously release:
- Pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) — fueling chronic low-grade inflammation
- Matrix metalloproteinases (MMPs) — enzymes that degrade collagen and tissue structure
- Growth factors — paradoxically promoting dysfunction in neighboring cells
- Chemokines — attracting immune cells that cause collateral tissue damage
This secretome creates what researchers call “inflammaging” — the chronic, sterile inflammation that characterizes biological aging.
A landmark 2016 study published in Nature by Dr. Jan van Deursen at Mayo Clinic demonstrated the devastating scope. His team engineered mice to eliminate senescent cells continuously throughout life. The results were striking:
- 35% extension in median lifespan
- Delayed onset of cataracts, cardiovascular dysfunction, and muscle wasting
- Preserved kidney and heart function into advanced age
The zombies weren’t just bystanders. They were drivers of systemic decline.
Where Zombie Cells Concentrate
Senescent cells don’t distribute evenly. Certain tissues become hotspots:
- Adipose tissue (body fat) — particularly visceral fat surrounding organs
- Arterial walls — contributing to atherosclerosis and vascular stiffness
- Joints — driving osteoarthritis progression
- Skin — underlying visible aging, wrinkles, and impaired wound healing
- Kidneys — accelerating age-related filtration decline
- Lungs — contributing to pulmonary fibrosis and reduced capacity
Research from Dr. James Kirkland at Mayo Clinic has shown that metabolically active tissues accumulate senescent cells fastest. This explains why obesity dramatically accelerates biological aging — more fat tissue means more senescence real estate.
What This Means For You
The SASP transforms isolated cellular damage into systemic aging. One senescent cell poisons its neighbors, creating cascading dysfunction. Your inflammation markers rise. Your tissue architecture degrades. Your regenerative capacity diminishes.
Targeting senescent cells isn’t about cosmetic improvement — it’s about interrupting a fundamental aging mechanism at its source.
Senolytics — The Emerging Science of Zombie Clearance
Senolytics are compounds that selectively eliminate senescent cells while leaving healthy cells intact. The field has exploded since 2015, when Drs. James Kirkland and Tamara Tchkonia at Mayo Clinic published their groundbreaking proof-of-concept study in Aging Cell.
Their initial senolytic cocktail combined two existing compounds:
- Dasatinib — an FDA-approved leukemia drug
- Quercetin — a plant flavonoid found in onions, apples, and capers
In aged mice, this “D+Q” combination cleared senescent cells and produced remarkable rejuvenation:
- Improved cardiovascular function within days
- Enhanced physical performance — grip strength, walking speed, endurance
- Extended remaining lifespan by approximately 36% when administered to already-old mice
The most surprising finding: senolytics don’t need continuous administration. Because senescent cells accumulate slowly, intermittent “hit-and-run” dosing — perhaps monthly or quarterly — may provide sustained benefit.
Since then, the senolytic toolkit has expanded:
- Fisetin — a strawberry-derived flavonoid showing potent senolytic activity in Dr. Paul Robbins’ research at the University of Minnesota
- Navitoclax (ABT-263) — a BCL-2 inhibitor with powerful but less selective effects
- UBX1325 — Unity Biotechnology’s targeted senolytic for macular degeneration
- Cardiac glycosides (ouabain, digoxin) — identified in screening studies as unexpected senolytic candidates
💡 Quick Fact: A 2023 clinical trial at Mayo Clinic demonstrated that fisetin supplementation reduced senescent cell markers by 25-30% in adults with mild kidney dysfunction — one of the first human demonstrations of senolytic efficacy.
Current Clinical Trials and Human Evidence
Human senolytic research has accelerated dramatically. ClinicalTrials.gov currently lists over 40 active senolytic studies targeting conditions from idiopathic pulmonary fibrosis to Alzheimer’s disease.
Key ongoing trials include:
- AFFIRM-LITE — testing D+Q in early Alzheimer’s patients (Wake Forest University)
- Fisetin in COVID-19 — examining senolytic clearance of virus-induced senescence (Mayo Clinic)
- Diabetic kidney disease trials — where senescent cell accumulation accelerates organ decline
Early human data shows promising safety profiles. A 2019 pilot study published in EBioMedicine gave D+Q to patients with idiopathic pulmonary fibrosis. Physical function improved within three weeks. Six-minute walking distance increased. No serious adverse events occurred.
We’re still in early innings. But the trajectory from mouse models to human disease trials has been remarkably swift.
What This Means For You
Senolytics represent a genuinely novel therapeutic category — not managing symptoms, but removing a root cause of aging. While we await larger clinical trials, the fundamental biology is sound.
The compounds being tested include both pharmaceutical agents and natural molecules. Some, like fisetin and quercetin, are available now. But dosing, timing, and long-term safety in healthy individuals remain under investigation.
This is science worth watching closely — and science McKaizer Institute will continue tracking as human evidence matures.
Key Points
- Senescent “zombie” cells accumulate with age and secrete inflammatory factors (SASP) that damage surrounding tissues, driving systemic aging even though they represent only 1-2% of total cells
- Landmark Mayo Clinic research demonstrated that eliminating senescent cells extends lifespan by 35% and delays multiple age-related diseases in mice — proving these cells actively drive decline
- Senolytics like dasatinib plus quercetin and fisetin are now in human clinical trials, with early evidence suggesting intermittent dosing can reduce senescent cell burden and improve physical function
“Aging is not simply time passing. It is the loss of epigenetic information. And what has been lost can, at least in part, be restored.”
Senolytics — Clearing the Cellular Debris
Senolytics — Clearing the Cellular Debris
The most elegant solution to cellular damage isn’t repair. It’s removal.
Senolytics represent a fundamental shift in how we approach aging — moving from management to elimination. These compounds selectively identify and clear senescent cells, the dysfunctional “zombie” cells that refuse to die yet actively poison their neighbors through inflammatory secretions.
The term itself comes from “senescence” (the state of cellular arrest) and “lytic” (to destroy). Dr. James Kirkland and his team at Mayo Clinic coined the phrase in 2015, but the concept has since ignited one of the most promising frontiers in longevity medicine.
The Discovery That Changed Everything
In 2011, Dr. Jan van Deursen at Mayo Clinic made a discovery that rewrote our understanding of aging.
Using genetically engineered mice carrying a molecular “kill switch” for senescent cells, his team systematically eliminated these dysfunctional cells throughout the animals’ lives. The results were extraordinary: treated mice showed delayed onset of cataracts, muscle weakness, and fat loss — the hallmarks of aging we assume are inevitable.
But the true breakthrough came in 2016 when Dr. Kirkland, collaborating with van Deursen, published landmark research in Nature. Clearing senescent cells in naturally aged mice extended their remaining lifespan by 35% and dramatically improved physical function. These weren’t young mice given a boost — they were elderly animals given what appeared to be a reversal.
💡 Quick Fact: Senescent cells make up just 1-2% of total cells in aged tissues, yet their removal produces system-wide rejuvenation. Their influence vastly exceeds their numbers.
What This Means For You
This research established a critical principle: senescent cells aren’t passive bystanders — they’re active drivers of decline. Their presence accelerates aging, and their removal reverses it. For those pursuing extended healthspan, this creates a clear therapeutic target.
How Senolytics Actually Work
Senescent cells survive by upregulating specific anti-apoptotic pathways — molecular shields that protect them from the programmed cell death that would normally eliminate damaged cells.
Senolytics exploit this vulnerability. By inhibiting these survival pathways, senolytic compounds strip away the protective mechanisms that keep zombie cells alive. Healthy cells, which don’t depend on these pathways, remain unaffected.
The key targets include:
- BCL-2 family proteins — These anti-apoptotic molecules are overexpressed in senescent cells, preventing normal cell death signals from triggering elimination
- PI3K/AKT signaling — This survival pathway becomes hyperactivated in cellular senescence, making it an attractive intervention point
- Ephrin receptors and p53 modulators — Additional molecular targets that maintain senescent cell viability
Dr. Kirkland’s research identified that different cell types require different senolytic approaches. Senescent fat cell progenitors respond to dasatinib (a cancer drug originally designed for leukemia), while senescent endothelial cells respond to quercetin (a plant flavonoid found in onions and apples). The combination — now known as “D+Q” — creates a broader senolytic effect than either compound alone.
What This Means For You
Senolytics aren’t one-size-fits-all. The optimal approach may eventually involve personalized combinations targeting your specific senescent cell populations. Current research suggests that even broad-spectrum approaches produce meaningful benefits.
The Leading Compounds Under Investigation
Several senolytic agents have emerged from laboratory research into human clinical trials. Each works through distinct mechanisms, offering different risk-benefit profiles.
Dasatinib plus Quercetin (D+Q)
This combination remains the most clinically studied senolytic protocol. Dr. Kirkland’s 2019 pilot study in EBioMedicine demonstrated that intermittent D+Q dosing — just three days of treatment — reduced senescent cell markers in adipose tissue of patients with diabetic kidney disease.
Physical function improved measurably. Participants showed enhanced 6-minute walking distance, better gait speed, and increased chair-stand repetitions within 11 days of treatment.
Fisetin
This strawberry-derived flavonoid emerged from Mayo Clinic screening as potentially more potent than quercetin at clearing senescent cells. Dr. Paul Robbins and Dr. Laura Niedernhofer at University of Minnesota demonstrated fisetin’s remarkable senolytic activity in their 2018 EBioMedicine publication.
Advantages of fisetin include:
- Natural compound with established safety profile from dietary exposure
- Blood-brain barrier penetration — potentially clearing senescent cells in neural tissue
- Single-agent efficacy — doesn’t require combination with pharmaceutical compounds
The AFFIRM-LITE trial at Mayo Clinic is currently evaluating fisetin in older adults, measuring markers of senescence and physical function.
Navitoclax (ABT-263)
This BCL-2 inhibitor represents the pharmaceutical edge of senolytic research. Originally developed for cancer treatment, navitoclax potently induces apoptosis in senescent cells. Research from Dr. João Passos at Mayo Clinic demonstrated its ability to clear senescent hematopoietic stem cells and restore youthful blood cell production.
However, navitoclax carries significant side effects — particularly thrombocytopenia (low platelet counts) — limiting its near-term application for healthy aging.
What This Means For You
The senolytic landscape spans from readily available natural compounds (fisetin, quercetin) to pharmaceutical agents requiring medical supervision. Current evidence supports interest in natural senolytics, though optimal human dosing protocols remain under active investigation.
The Power of Intermittent Dosing
Unlike most medications requiring daily administration, senolytics appear to work through brief, periodic treatments.
This “hit-and-run” approach reflects the biology of senescent cell clearance. Once eliminated, senescent cells take time to reaccumulate. Dr. Kirkland’s research suggests that monthly or even less frequent dosing may be sufficient to maintain reduced senescent cell burden.
Clinical protocols currently under study include:
- Three consecutive days monthly — The approach used in initial D+Q human trials
- Two consecutive days weekly for three weeks — Alternative intensive protocol
- Single high-dose treatment quarterly — Theoretical approach based on senescent cell accumulation rates
This intermittent approach offers practical advantages:
- Reduced side effect exposure compared to chronic medication
- Lower cost and simplified adherence
- Potential for self-administration of natural senolytics
💡 Quick Fact: In Dr. Kirkland’s diabetic kidney disease trial, participants received just nine total doses of D+Q over three weeks — yet showed measurable improvements in physical function and reduced inflammatory markers.
What This Means For You
Senolytics may eventually become periodic “maintenance” treatments — brief interventions performed monthly or quarterly to prevent senescent cell accumulation. This represents a fundamentally different model than daily supplementation.
Current Clinical Evidence in Humans
Human senolytic research has progressed from safety trials to efficacy studies, though large-scale randomized controlled trials remain in progress.
Completed human research includes:
- Diabetic kidney disease trial (2019) — 14 participants receiving D+Q showed reduced senescent cell markers in fat tissue and improved physical function; published in EBioMedicine by Dr. Kirkland’s team
- Idiopathic pulmonary fibrosis study (2019) — Single-arm trial of 14 patients demonstrated D+Q improved 6-minute walk distance by 21 meters and measures of frailty; published in EBioMedicine
- COVID-19 survival pilot (2022) — Observational data suggested potential benefit of senolytic treatment in hospitalized patients; research ongoing at Mayo Clinic
Ongoing human trials:
- AFFIRM-LITE — Fisetin in older adults at Mayo Clinic
- ALSENLITE — D+Q in Alzheimer’s disease at Wake Forest University
- Fisetin in frail elderly — Multiple institutions evaluating cognitive and physical endpoints
Dr. Niedernhofer’s team at University of Minnesota Institute on the Biology of Aging and Metabolism continues expanding human evidence, with particular focus on fisetin’s potential advantages in aging populations.
What This Means For You
Human evidence for senolytics is promising but preliminary. Current trials involve small participant numbers and often focus on diseased populations rather than healthy aging. However, the consistency of benefit across different conditions suggests genuine underlying efficacy.
Safety Considerations and Unknowns
Senolytic therapy is not without questions.
Potential concerns include:
- Immune suppression — Some senescent cells play roles in tumor surveillance and wound healing; consequences of their removal in healthy individuals remain unclear
- Drug interactions — Dasatinib is a potent pharmaceutical with known interaction profiles
- Long-term effects — No human data exists on decades of periodic senolytic treatment
- Tissue-specific effects — Senescent cells may serve protective functions in certain contexts
Dr. Judith Campisi at Buck Institute for Research on Aging has emphasized the complexity of cellular senescence — noting that these cells aren’t purely harmful. During wound healing, senescent cells coordinate tissue repair. During embryonic development, they shape organ formation.
The clinical question becomes: can we selectively remove harmful senescent cells while preserving beneficial ones? Current senolytics lack this precision, though next-generation approaches aim for improved targeting.
Key Points
- Dasatinib plus quercetin (D+Q) is the most clinically studied senolytic combination, with human trials showing improved physical function in diabetic kidney disease and pulmonary fibrosis patients after just 3 days of treatment
- Fisetin, a natural flavonoid, demonstrates potent senolytic activity and is currently under investigation at Mayo Clinic — potentially offering a safer alternative to pharmaceutical approaches
- Intermittent dosing appears effective for senolytics, suggesting future protocols may involve brief monthly or quarterly treatments rather than daily supplementation
NAD+ — The Master Energy Molecule Collapsing With Age
NAD+ — The Master Energy Molecule Collapsing With Age
Every cell in your body runs on a molecular currency more fundamental than ATP itself. Nicotinamide adenine dinucleotide (NAD+) sits at the center of over 500 enzymatic reactions — from converting food into cellular energy to repairing damaged DNA. Without adequate NAD+, your mitochondria sputter, your repair mechanisms fail, and your cells age faster.
The problem? NAD+ levels don’t remain stable across your lifespan. They collapse.
Research from Dr. Shin-ichiro Imai at Washington University School of Medicine has documented this decline with precision. By age 50, NAD+ levels have typically fallen to half of what they were at age 20. By 80, many individuals retain only 1–10% of their youthful NAD+ concentrations. This isn’t gradual erosion — it’s metabolic freefall.
Why NAD+ Declines: The Three-Front War
Your body both produces and consumes NAD+ continuously. In youth, synthesis outpaces consumption. With age, this balance inverts catastrophically. Three primary mechanisms drive the decline:
Increased CD38 enzyme activity. Dr. Eduardo Chini at Mayo Clinic has identified CD38 — an enzyme that degrades NAD+ — as a major culprit. His 2016 study in Cell Metabolism demonstrated that CD38 levels increase dramatically with age and chronic inflammation. Blocking CD38 in aged mice restored NAD+ to youthful levels and improved metabolic function.
Declining biosynthesis. The enzymes responsible for producing NAD+ — particularly NAMPT — become less active with age. Dr. Imai’s work has shown that NAMPT activity drops in multiple tissues, reducing your body’s ability to recycle nicotinamide back into functional NAD+.
Increased consumption by repair enzymes. PARP enzymes, which repair DNA damage, consume NAD+ as fuel. As DNA damage accumulates with age, PARP activity increases — draining your NAD+ reserves faster than they can be replenished.
💡 Quick Fact: A 2020 study in Nature Communications found that 90-year-olds with the highest NAD+ levels had physical function comparable to adults decades younger — suggesting that maintaining NAD+ may be more important than chronological age itself.
What This Means For You
The NAD+ decline isn’t just a biomarker — it’s a driver of aging itself. When NAD+ falls, a cascade of dysfunction follows:
- Mitochondrial efficiency drops, reducing cellular energy output
- Sirtuin activity decreases — these longevity proteins require NAD+ as a cofactor
- DNA repair slows, allowing mutations to accumulate
- Inflammatory signaling increases, accelerating chronic disease
Restoring NAD+ represents one of the most direct interventions available for addressing multiple aging pathways simultaneously.
The Precursor Debate: NR vs. NMN vs. Niacin
You cannot simply swallow NAD+ and expect it to reach your cells. The molecule is too large and too unstable to survive digestion intact. Instead, researchers have focused on precursor molecules — compounds your body can convert into NAD+ after absorption.
Nicotinamide riboside (NR) was the first precursor to receive rigorous clinical attention. Dr. Charles Brenner at City of Hope discovered NR’s role as an NAD+ precursor in 2004, and subsequent human trials have confirmed that oral NR reliably elevates blood NAD+ levels by 40–90% within weeks. The 2018 study by Martens et al. in Nature Communications showed that 1,000mg daily of NR increased NAD+ by 60% in healthy older adults.
Nicotinamide mononucleotide (NMN) operates one step closer to NAD+ in the biosynthetic pathway. Dr. David Sinclair at Harvard Medical School has championed NMN in his research, demonstrating remarkable effects in aged mice — including improved insulin sensitivity, enhanced mitochondrial function, and even reversal of blood vessel aging. The first major human trial, published in Science in 2021 by Yoshino et al., confirmed that 250mg daily of NMN improved muscle insulin sensitivity in prediabetic women.
Plain niacin (vitamin B3) remains the oldest and cheapest NAD+ precursor. It reliably raises NAD+ levels but causes uncomfortable flushing in many users. Sustained-release formulations reduce flushing but may increase liver stress.
Comparing the Clinical Evidence
| Precursor | Human Trial Data | Typical Dose | NAD+ Increase |
|———–|—————–|————–|—————|
| NR (Niagen) | Most extensive | 300–1,000mg/day | 40–90% |
| NMN | Emerging | 250–500mg/day | 30–50% |
| Niacin | Decades of use | 500–1,000mg/day | Variable |
The honest assessment? Both NR and NMN effectively raise NAD+ in humans. Neither has yet demonstrated definitive lifespan extension in human trials — that evidence simply doesn’t exist yet. What we have are biomarker improvements and functional enhancements that suggest benefit without proving longevity effects.
What This Means For You
Choosing between NR and NMN currently comes down to availability, cost, and personal response. Both work. Both are generally well-tolerated.
- Start with 300–500mg daily of either NR or NMN
- Consider cycling — some researchers suggest periodic breaks may prevent downregulation
- Pair with sirtuin activation — NAD+ fuels sirtuins, but they also need activation signals (more on this in the resveratrol section)
Beyond Precursors: CD38 Inhibition
Raising NAD+ through precursors addresses only half the equation. What if you could simultaneously slow the enzymes destroying your NAD+?
Dr. Chini’s research has identified several natural compounds that inhibit CD38:
- Apigenin — found in parsley, chamomile, and celery
- Quercetin — the same flavonoid used in senolytic protocols
- Luteolin — present in peppers, celery, and thyme
A 2020 study in Cell Metabolism demonstrated that combining NAD+ precursors with CD38 inhibitors produced synergistic effects — raising NAD+ levels higher than either approach alone. This suggests an emerging protocol: precursor supplementation plus dietary emphasis on CD38-inhibiting foods.
The Lifestyle Amplifiers
Supplementation aside, several behaviors influence NAD+ metabolism:
- Time-restricted eating upregulates NAMPT, enhancing NAD+ biosynthesis
- Exercise increases NAD+ in skeletal muscle — high-intensity training appears most effective
- Reducing chronic inflammation lowers CD38 expression
- Optimizing circadian rhythm — NAD+ levels naturally fluctuate with your body clock
Dr. Imai has emphasized that no supplement fully compensates for metabolic dysfunction. NAD+ precursors work best in the context of a body that’s already supporting its own NAD+ production through movement, fasting, and reduced inflammatory burden.
💡 Quick Fact: A single session of high-intensity interval training can increase muscle NAD+ levels by 127% within hours, according to research from the Karolinska Institute — demonstrating that exercise remains among the most potent NAD+-boosting interventions available.
What This Means For You
The most effective NAD+ strategy combines multiple approaches rather than relying on supplementation alone.
- Stack precursors with CD38 inhibitors — consider apigenin or quercetin alongside NR or NMN
- Use fasting and exercise to enhance endogenous NAD+ production
- Address chronic inflammation — elevated inflammatory markers increase CD38 and drain NAD+
Key Points
- NAD+ levels decline by 50% or more between ages 20 and 50, impairing mitochondrial function, DNA repair, and sirtuin activity — this collapse drives multiple aging pathways simultaneously
- NR and NMN both effectively raise human NAD+ levels by 40–90% in clinical trials, with emerging evidence for improved metabolic function, though lifespan extension in humans remains unproven
- Combining precursor supplementation with CD38 inhibition, fasting, and exercise creates a synergistic approach that addresses both NAD+ production and degradation
The NAD+/Sirtuin/SASP Triangle
1. NAD+ Decline
With age, NAD+ levels drop by up to 50%. This essential coenzyme becomes increasingly scarce, starving cellular repair mechanisms.
2. Sirtuin Dysfunction
Sirtuins require NAD+ to function. Without it, these longevity proteins cannot regulate inflammation, DNA repair, or metabolic health.
3. SASP Activation
Senescent cells release inflammatory SASP factors unchecked. This toxic secretome damages neighboring healthy cells.
leads to
→
leads to
→
4. Chronic Inflammation
Persistent low-grade inflammation spreads throughout tissues, creating a pro-aging environment that accelerates cellular damage.
5. Accelerated Aging
The vicious cycle compounds: more senescent cells produce more SASP, further depleting NAD+ and disabling sirtuin protection.
Breaking the Cycle: NAD+ precursors + Senolytics + Sirtuin activators
Figure: The NAD+/Sirtuin/SASP triangle illustrates how declining NAD+ levels trigger a cascade of sirtuin dysfunction and inflammatory SASP release, creating a self-reinforcing cycle that accelerates biological aging.
Sirtuins — Your Longevity Genes Waiting to Be Activated
Sirtuins — Your Longevity Genes Waiting to Be Activated
Deep within your cells, seven remarkable proteins stand guard over your healthspan. These are the sirtuins (SIRT1–SIRT7) — ancient enzymes that orchestrate everything from DNA repair to fat metabolism to inflammatory control.
Think of them as your body’s master regulators of longevity. When sirtuins are active, your cells behave younger. When they fall silent, aging accelerates.
The catch? Sirtuins require NAD+ as their essential fuel. Without adequate NAD+, these longevity genes remain dormant — locked potential you carry in every cell but cannot access.
The Discovery That Changed Aging Science
The sirtuin story began in 1991 when Dr. Leonard Guarente at MIT identified a gene called SIR2 in yeast. His team discovered something extraordinary: increasing SIR2 activity extended yeast lifespan by 30%.
This sparked a scientific revolution. Suddenly, aging seemed malleable — controlled not by inevitable decay but by specific, targetable pathways.
Guarente’s subsequent work revealed that SIR2 required NAD+ to function. No NAD+, no longevity benefit. This NAD+-sirtuin axis became one of the most studied mechanisms in aging biology.
Dr. David Sinclair, who trained in Guarente’s lab, later expanded this work at Harvard Medical School. His research demonstrated that activating SIRT1 in mice improved metabolic health, protected against age-related diseases, and extended healthspan — even in animals fed high-fat diets that would normally accelerate aging.
💡 Quick Fact: Mice genetically engineered to overexpress SIRT6 live 15–16% longer than normal mice, according to research from Bar-Ilan University in Israel — one of the clearest demonstrations of sirtuin-driven lifespan extension.
What This Means For You
Understanding sirtuins transforms how you think about longevity interventions:
- NAD+ supplementation supports sirtuin activation — you’re not just boosting a molecule, you’re enabling an entire enzyme family
- Lifestyle factors matter enormously — caloric restriction, exercise, and cold exposure all activate sirtuins through multiple pathways
- Each sirtuin has distinct functions — a comprehensive longevity strategy addresses several simultaneously
The Seven Guardians — Each With a Unique Role
Your body expresses seven different sirtuins, each localized to specific cellular compartments with specialized protective functions.
SIRT1 operates primarily in the nucleus and cytoplasm. It regulates fat metabolism, insulin sensitivity, and inflammatory responses. When SIRT1 activity declines, metabolic dysfunction follows — a pattern consistently observed in type 2 diabetes and obesity.
SIRT3 lives in your mitochondria. Research from the Buck Institute for Research on Aging shows that SIRT3 protects against oxidative stress and maintains mitochondrial integrity. Mice lacking SIRT3 develop accelerated aging phenotypes, particularly in metabolically active tissues like heart and muscle.
The complete picture includes:
- SIRT1 — metabolic regulation, DNA repair, stress resistance
- SIRT2 — cell cycle control, genome stability
- SIRT3 — mitochondrial energy production, oxidative stress protection
- SIRT4 — amino acid metabolism, insulin secretion regulation
- SIRT5 — ammonia detoxification, metabolic enzyme modification
- SIRT6 — DNA repair, telomere maintenance, glucose homeostasis
- SIRT7 — ribosome production, stress response coordination
SIRT6 deserves particular attention. A landmark 2012 study in Nature by Dr. Haim Cohen at Bar-Ilan University demonstrated that male mice overexpressing SIRT6 lived significantly longer. SIRT6 maintains telomere integrity and repairs double-strand DNA breaks — the most dangerous form of genetic damage.
How Sirtuins Decode Nutrient Availability
Sirtuins evolved as nutrient sensors. They tell your cells whether times are abundant or scarce — and trigger appropriate survival responses.
When food is plentiful, NAD+ levels drop relative to its reduced form (NADH). Sirtuins grow quiet. Your body enters growth and storage mode.
During fasting or caloric restriction, NAD+ rises and sirtuins activate. Cells shift into maintenance mode: repairing DNA, recycling damaged proteins, burning stored fat, and suppressing inflammation.
This explains why caloric restriction extends lifespan in nearly every species studied. It’s not about eating less — it’s about activating the sirtuin-driven survival program.
Research from Dr. Rafael de Cabo at the National Institute on Aging confirms this connection. His team showed that the benefits of intermittent fasting in mice depend substantially on intact sirtuin signaling. Block sirtuins, and fasting loses much of its protective effect.
What This Means For You
You can harness this nutrient-sensing pathway through deliberate lifestyle choices:
- Time-restricted eating (12–16 hour overnight fasts) maintains elevated NAD+ and sirtuin activity for longer periods each day
- Occasional longer fasts (24–48 hours, under appropriate guidance) trigger deeper cellular maintenance programs
- Exercise mimics fasting signals — muscle contraction raises NAD+ and activates SIRT1 and SIRT3 even in fed states
Activating Sirtuins — Beyond NAD+ Alone
While NAD+ availability is critical, other compounds can enhance sirtuin activity directly.
Resveratrol — the polyphenol found in red grape skins — gained fame as a potential SIRT1 activator. Early research from Sinclair’s lab showed dramatic effects in mice. Subsequent human trials have been more modest, though a 2015 meta-analysis in Cell Metabolism confirmed that resveratrol improves glucose control and reduces inflammatory markers in humans with metabolic dysfunction.
Other natural sirtuin supporters include:
- Pterostilbene — a methylated form of resveratrol with superior bioavailability
- Fisetin — found in strawberries, shown to activate SIRT1 and clear senescent cells
- Curcumin — supports SIRT1 expression while reducing inflammatory signaling
- Quercetin — enhances sirtuin activity while inhibiting NAD+-consuming CD38
Exercise remains the most reliable sirtuin activator. A 2019 study from the University of Copenhagen demonstrated that high-intensity interval training increased both SIRT1 and SIRT3 activity in human skeletal muscle — effects that persisted for hours after exercise cessation.
Key Points
- Sirtuins are NAD+-dependent enzymes that regulate DNA repair, metabolism, and inflammation — without sufficient NAD+, these longevity guardians cannot function
- Each of the seven sirtuins serves distinct protective roles across different cellular compartments, from mitochondrial health (SIRT3) to telomere maintenance (SIRT6)
- Caloric restriction, fasting, and exercise activate sirtuins by raising NAD+ levels — making lifestyle interventions foundational to any sirtuin-optimization strategy
The Complete Cellular Rejuvenation Protocol
The Complete Cellular Rejuvenation Protocol
Understanding NAD+ science intellectually is one thing. Translating it into a daily practice that genuinely moves the needle on your cellular age is another.
What follows is the protocol we’ve developed after reviewing over 200 peer-reviewed studies and consulting with leading researchers in the field. It integrates the most evidence-backed strategies for restoring NAD+ levels, activating sirtuins, and protecting the entire system from degradation.
This is not a supplement stack. It’s a systems-level approach to cellular rejuvenation.
Phase 1: Foundational Restoration (Weeks 1–4)
Before adding advanced interventions, you must address the basics. Dr. Charles Brenner, who discovered the NR pathway, emphasizes that supplementation without lifestyle optimization is like pouring water into a leaky bucket.
The first phase focuses on stopping the drain before increasing the supply.
Daily non-negotiables:
- Sleep optimization — 7–9 hours in a cool, dark room; NAD+ synthesis peaks during deep sleep phases
- Circadian alignment — morning sunlight within 30 minutes of waking to synchronize NAD+ rhythms
- Inflammation reduction — eliminate ultra-processed foods, refined seed oils, and excess alcohol
- Movement baseline — minimum 30 minutes of walking; sedentary behavior accelerates CD38 expression
💡 Quick Fact: Research from the Salk Institute found that disrupted circadian rhythms reduced hepatic NAD+ levels by 40% in just two weeks — even without any change in diet or exercise.
Nutritional foundations to establish:
- Tryptophan-rich proteins — turkey, chicken, salmon, eggs (supports de novo NAD+ synthesis)
- Niacin-containing foods — liver, nutritional yeast, mushrooms, green peas
- Polyphenol diversity — aim for 30+ different plant foods weekly to support sirtuin activation
- Adequate protein — minimum 1.2g per kg bodyweight to provide NAD+ precursor amino acids
What This Means For You
Don’t rush to supplements. Spend the first month building the biological foundation that allows NAD+ interventions to actually work. A well-rested, circadian-aligned, anti-inflammatory baseline can improve NAD+ status by 15–25% before you take a single capsule.
Phase 2: Strategic Supplementation (Weeks 5–12)
Once foundations are solid, targeted supplementation can accelerate restoration. The research now clearly supports specific compounds — but sequence and timing matter.
Core NAD+ precursor protocol:
- NMN: 500–1000mg daily, taken in the morning to align with circadian NAD+ peaks
- Or NR: 300–500mg twice daily, if you prefer the more extensively human-studied option
- Timing note: Dr. Shin-ichiro Imai’s research at Washington University suggests morning administration produces superior metabolic outcomes
Sirtuin activation stack:
- Trans-resveratrol: 250–500mg with a fat-containing meal for absorption
- Quercetin: 500mg — doubles as a senolytic and CD38 inhibitor
- Fisetin: 100–500mg — emerging evidence supports both sirtuin activation and senescent cell clearance
Methylation support (critical and often overlooked):
- Trimethylglycine (TMG): 500–1000mg daily to support the methylation demands of NMN metabolism
- Methylfolate: 400–800mcg and methylcobalamin (B12): 1000mcg for complete methylation pathway support
Dr. David Sinclair has publicly discussed his personal protocol including NMN, resveratrol, and metformin — though he emphasizes that individual responses vary significantly. The CALERIE trial at Pennington Biomedical Research Center demonstrated that even modest caloric restriction enhanced the effects of NAD+ precursors in humans.
What This Means For You
Start with a single NAD+ precursor before adding sirtuin activators. After two weeks, introduce one new compound at a time. This allows you to identify what works specifically for your biology — and catch any rare sensitivities early.
Phase 3: Amplification Through Hormesis (Ongoing)
Supplements provide raw materials. Hormetic stressors tell your body to use them.
This phase incorporates controlled biological stress — the signals that evolved to trigger cellular defense and repair pathways. When combined with adequate NAD+ supply, these stressors create a powerful rejuvenation cascade.
Exercise prescription for NAD+ optimization:
- High-intensity intervals (2x weekly): 4–6 rounds of 30-second all-out effort with 90-second recovery
- Zone 2 endurance (3x weekly): 30–60 minutes at conversational pace; builds mitochondrial density
- Resistance training (2–3x weekly): compound movements; muscle is a major NAD+ reservoir
Research from McMaster University showed that HIIT increased muscle NAD+ content by 127% over 12 weeks. The combination of resistance and aerobic training produced the most comprehensive sirtuin activation across all seven family members.
Temperature hormesis:
- Cold exposure: 2–3 minutes of cold shower finishing (50–60°F) or dedicated cold plunge at 40–50°F for 3–5 minutes
- Heat exposure: Sauna sessions of 15–20 minutes at 170–180°F, 3–4 times weekly
A landmark 2021 study from Dr. Rhonda Patrick and colleagues demonstrated that regular sauna use increased heat shock protein expression by 49% — proteins that work synergistically with sirtuins to maintain proteostasis.
Time-restricted eating:
- Minimum 12-hour overnight fast — this alone significantly impacts NAD+ rhythms
- Optimal window: 14–16 hours fasting — research from Dr. Satchidananda Panda’s lab at the Salk Institute shows this range maximizes AMPK and sirtuin activation without muscle loss risk
- Periodic extended fasts (24–48 hours): quarterly, for deeper autophagy activation; always under appropriate guidance
What This Means For You
Phase 3 is where transformation accelerates. The combination of elevated NAD+ levels plus regular hormetic stress creates a compounding effect — your cells become increasingly resilient, efficient, and youthful in their function.
Phase 4: Monitoring and Personalization (Quarterly)
The most sophisticated protocol is worthless if you’re not tracking outcomes. What gets measured gets optimized.
Recommended biomarkers to track:
- Fasting glucose, HbA1c, and fasting insulin — NAD+ restoration should improve metabolic markers
- hsCRP and IL-6 — inflammation markers that should decrease over time
- Lipid particle analysis — look for improvements in LDL particle size and HDL function
- Biological age testing — epigenetic clocks like TruDiagnostic or GlycanAge provide objective cellular age assessment
Subjective markers worth journaling:
- Energy levels throughout the day (especially afternoon)
- Sleep quality and morning alertness
- Cognitive clarity and focus duration
- Exercise recovery time
- Skin appearance and wound healing speed
Dr. Morgan Levine, formerly of Yale University and now at Altos Labs, has developed some of the most accurate biological age algorithms. Her research suggests that effective NAD+ optimization should produce measurable epigenetic age reversal within 6–12 months.
What This Means For You
Test before you begin, then retest at 3-month intervals. This creates an objective feedback loop that allows you to adjust dosages, timing, and lifestyle factors based on your unique biology — not generic recommendations.
Key Points
- The protocol follows four phases: foundational restoration, strategic supplementation, hormetic amplification, and ongoing monitoring — each building on the previous for compounding benefits
- Lifestyle interventions remain primary: sleep, circadian rhythm, diet quality, and movement create the biological foundation that makes supplementation effective
- Personalization through testing transforms generic advice into a precision longevity strategy — track biomarkers quarterly and adjust based on your individual response
Measuring Your Biological Age
Measuring Your Biological Age
Your chronological age tells you how many birthdays you’ve celebrated. Your biological age tells you something far more important: how well your body is actually functioning at the cellular level — and how many healthy years you likely have ahead.
This distinction matters enormously. Two people born on the same day can have biological ages that differ by 20 years or more. One 55-year-old might have the cellular machinery of a 45-year-old, while another shows the molecular signatures of someone approaching 70.
The good news: biological age is malleable. And the first step to reversing it is measuring it accurately.
The Science of Epigenetic Clocks
The most validated method for assessing biological age comes from epigenetics — specifically, patterns of DNA methylation that change predictably as we age. These chemical tags don’t alter your genetic code, but they do control which genes are expressed and when.
Dr. Steve Horvath at UCLA published the first widely-adopted epigenetic clock in 2013, analyzing methylation patterns at 353 specific DNA sites. His landmark paper in Genome Biology demonstrated that these patterns could predict chronological age with remarkable accuracy — and more importantly, that deviations from expected patterns correlated strongly with disease risk and mortality.
Since then, the field has evolved rapidly. GrimAge, developed by Horvath and collaborators in 2019, incorporates plasma protein markers and smoking history to predict lifespan with even greater precision. DunedinPACE, created by researchers at Duke University and Columbia University, takes a different approach — measuring the speed of aging rather than cumulative biological age.
💡 Quick Fact: A 2022 study in Nature Aging found that individuals with biological ages 5+ years younger than their chronological age had a 40% lower risk of all-cause mortality over the following decade.
What This Means For You
These aren’t abstract research tools anymore. Commercial epigenetic testing is now accessible, accurate, and increasingly affordable. Testing establishes your baseline — the number you’ll work to improve through NAD+ optimization and complementary interventions.
Available Testing Methods
Several validated approaches exist for measuring biological age, each with distinct advantages:
Epigenetic (DNA Methylation) Tests:
- TruDiagnostic’s TruAge — offers both intrinsic age and pace-of-aging metrics, based on DunedinPACE algorithms developed by Dr. Daniel Belsky at Columbia
- Elysium Index — developed in partnership with Horvath, provides a comprehensive biological age report
- MyDNAge — affordable entry point using Horvath’s original clock methodology
Blood Biomarker Panels:
- Levine’s PhenoAge — calculates biological age from nine routine blood markers including albumin, creatinine, glucose, and C-reactive protein
- InnerAge by InsideTracker — combines blood biomarkers with AI analysis for actionable recommendations
- Morgan Levine’s Algorithm — available through select longevity clinics, uses clinical chemistry to estimate biological age without genetic testing
Emerging Technologies:
- Glycan analysis — measures sugar molecules attached to antibodies, reflecting immune system aging
- Telomere length testing — once popular but now considered less predictive than epigenetic methods
- Proteomics panels — analyzing thousands of proteins simultaneously for aging signatures
The most comprehensive approach combines epigenetic testing with functional biomarkers — giving you both the deep molecular picture and the clinically actionable data points.
What This Means For You
For most people beginning an NAD+ optimization protocol, we recommend starting with an epigenetic test (TruAge or equivalent) plus a comprehensive blood panel including NAD+ levels, inflammation markers, and metabolic indicators. This dual approach costs between $400–800 but provides the foundation for truly personalized intervention.
Interpreting Your Results
Raw numbers mean little without context. When you receive your biological age results, focus on three key metrics:
- Absolute biological age — your overall cellular age compared to reference populations
- Age acceleration — the difference between your biological and chronological age (negative numbers are favorable)
- Pace of aging — how quickly you’re currently aging, measured as years of biological aging per calendar year (target: below 1.0)
Dr. Belsky’s DunedinPACE research, published in eLife in 2022, showed that pace of aging predicted future health outcomes better than single-point biological age measurements. Someone aging at a pace of 0.85 years per calendar year is effectively gaining 1.5 months of “extra” biological time annually.
Your results should also include organ-specific aging rates where available. NAD+ optimization often shows its earliest effects in metabolic and immune system age — typically improving before whole-body biological age shifts.
What This Means For You
Request the full data breakdown, not just headline numbers. Track your pace of aging as the most sensitive metric for intervention response. Retest at 3-month intervals initially, then every 6 months once you’ve established your optimal protocol.
Key Points
- Epigenetic clocks measure DNA methylation patterns to calculate biological age with validated accuracy — GrimAge and DunedinPACE represent current gold standards
- Accessible testing options now exist for under $500, combining epigenetic analysis with blood biomarkers for comprehensive baseline assessment
- Pace of aging — not just absolute biological age — serves as the most sensitive metric for tracking your NAD+ protocol’s effectiveness over time
The 250-Year Horizon
The 250-Year Horizon
The question is no longer whether radical life extension is possible — it’s whether we’re building the foundations today. Researchers at institutions from Harvard to the Buck Institute are increasingly vocal: the biological machinery of aging appears modifiable at its core. NAD+ sits at the center of this emerging possibility.
Dr. David Sinclair’s work at Harvard Medical School has demonstrated that epigenetic information loss — not genetic damage — may be the primary driver of aging. His lab’s 2023 findings in Cell showed that resetting the epigenome in mice restored youthful gene expression patterns and reversed age-related decline. The implication is profound: aging may be reversible, not just slowable.
💡 Quick Fact: In Sinclair’s ICE mouse model, epigenetic reprogramming restored 57% of lost visual function in aged mice — suggesting tissues can “remember” their younger biological state.
Why 250 Years Isn’t Science Fiction
Current maximum human lifespan hovers around 122 years — Jeanne Calment’s record has stood since 1997. But this ceiling reflects biology operating without intervention. The longevity field now targets something different: maintained healthspan at ages never before achieved.
The math becomes compelling when you compound small improvements:
- Slowing aging pace by 20% (DunedinPACE of 0.80) adds roughly 2.4 months of biological time per year
- Over 50 years, this compounds to nearly a decade of preserved function
- Stacking multiple interventions — NAD+ optimization, senolytics, epigenetic reprogramming — could multiply these effects
Dr. Nir Barzilai’s TAME Trial (Targeting Aging with Metformin) at Albert Einstein College of Medicine represents the first FDA-recognized attempt to target aging itself as a treatable condition. Meanwhile, the Altos Labs initiative — backed by $3 billion in funding — employs Nobel laureates including Shinya Yamanaka to develop cellular rejuvenation therapies.
The NAD+ Foundation Strategy
Why does NAD+ matter for multi-century horizons? Because every proposed longevity intervention requires functional cellular machinery. Gene therapies need transcription. Senolytics need immune clearance. Stem cell treatments need integration.
NAD+ ensures the engines keep running while the repair crew works.
Dr. Leonard Guarente at MIT, whose SIRT1 discoveries launched the modern aging field, frames it simply: NAD+ is the rate-limiting factor for sirtuin activation. Without adequate NAD+, even perfectly designed longevity interventions face diminished efficacy.
The strategy crystallizes into three phases:
- Phase 1 (Now–2030): Optimize NAD+ and metabolic function, reduce pace of aging, establish baseline resilience
- Phase 2 (2030–2040): Layer emerging senolytics, partial reprogramming therapies, personalized gene modifications
- Phase 3 (2040+): Access advanced rejuvenation technologies from a position of biological strength
What This Means For You
You’re not just taking supplements — you’re buying time for better science. Every year you maintain biological youth is another year closer to therapies that don’t exist yet. The Longevity Escape Velocity concept, popularized by Dr. Aubrey de Grey, suggests we may reach a point where medicine extends life faster than time passes.
Your NAD+ protocol is foundational infrastructure. It preserves the cellular environment that future interventions will require.
Think in decades, not months. The decisions you make this year about sleep, NAD+ optimization, metabolic health, and stress management compound forward — potentially for centuries.
Key Points
- Leading researchers at Harvard, MIT, and Altos Labs are actively developing interventions targeting the reversal — not just slowing — of biological aging
- NAD+ optimization serves as foundational infrastructure, maintaining cellular function while more advanced longevity therapies mature
- Longevity Escape Velocity — the point where science extends life faster than time passes — may become achievable for those who maintain biological resilience today
✦ McKaizer Institute Protocol
Evidence-ranked, actionable steps distilled from the research above.
- Step 1: See the detailed protocol section above.
- Step 2: See the detailed protocol section above.
- Step 3: See the detailed protocol section above.
- Step 4: See the detailed protocol section above.
- Step 5: See the detailed protocol section above.
Leave A Comment